← back to search

Samuel Agus

Palo Alto University · US
Area of research
Infectious Diseases · Neurology
Research interest
Research focused on Regimen and Clinical trial, with related work in Diuretic, Enzyme replacement therapy, Lenvatinib. Notable publications include 'A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial', 'A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme...', and 'Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a...'.
h-index
citations
77
works
5
NIH funding
primary concept
email

Recent publications

A feasibility open-label clinical trial utilizing second-generation artificial intelligence based on the constrained-disorder principle in patients with Parkinson's disease
IBRO Neuroscience Reports 2026cited by 0position: middledoi
A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis
Journal of public health research 2025cited by 4position: middledoi
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
Journal of Clinical Medicine 2024cited by 19position: middledoi
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Frontiers in Oncology 2024cited by 16position: middledoi
A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial
Biomedicine & Pharmacotherapy 2023cited by 38position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yaron Ilan · Hebrew University of Jerusalem4 papers (2023–2025)Noa Hurvitz · Hebrew University of Jerusalem4 papers (2023–2026)Marc Berg · Palo Alto University4 papers (2023–2025)Yotam Kolben · Hebrew University of Jerusalem2 papers (2023–2025) · 2 papers (2023–2024)Khurram Jamil · Rodin Therapeutics (United States)2 papers (2023–2025)Offer Amir · Hebrew University of Jerusalem1 papers (2023–2023) · 1 papers (2024–2024)David Arkadir · Hebrew University of Jerusalem1 papers (2026–2026) · 1 papers (2026–2026) · 1 papers (2026–2026)Marc Berg · Palo Alto University1 papers (2026–2026)Tama Dinur · Hebrew University of Jerusalem1 papers (2024–2024)Yoav Hershkovitz · Hebrew University of Jerusalem1 papers (2025–2025)Hillel S. Lehmann · Hadassah Medical Center1 papers (2026–2026)Henny Azmanov · Hebrew University of Jerusalem1 papers (2026–2026)Rabea Asleh · Hadassah Medical Center1 papers (2023–2023)Aron Popovtzer · Jerusalem Institute for Israel Studies1 papers (2024–2024)Shoshana Revel‐Vilk · Hebrew University of Jerusalem1 papers (2024–2024) · 1 papers (2024–2024)